Lifecore Biomedical
LFCR
90 hedge funds and large institutions have $252M invested in Lifecore Biomedical in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 34 increasing their positions, 35 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
3% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 35
1.33% less ownership
Funds ownership: 87.09% → 85.76% (-1.3%)
7% less funds holding
Funds holding: 97 → 90 (-7)
10% less capital invested
Capital invested by funds: $279M → $252M (-$26.9M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$1.17M |
| 2 |
TAM
Tocqueville Asset Management
New York
|
+$1.14M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$992K |
| 4 |
ICM
ISZO Capital Management
New York
|
+$638K |
| 5 |
CSC
Cove Street Capital
El Segundo,
California
|
+$491K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$2.96M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.2M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$977K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$577K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$573K |
LFCR Hedge Fund Activity: Q2 2022 in Review
90 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2022, worth a combined $252M — down 9.6% from $279M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LFCR and 5 opened new positions — a net loss of 5 holders — while 35 trimmed existing stakes and 34 added.
The largest buyer was 22NW LP, adding an estimated $1.17M. The largest seller was Fuller & Thaler Asset Management, exiting entirely with an estimated $2.96M sold.
- 90 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2022, down from 97 in Q1 2022.
- Funds reported $252M of Lifecore Biomedical stock for Q2 2022, down 9.6% quarter-over-quarter.
- 5 funds opened new Lifecore Biomedical positions in Q2 2022 and 10 closed out, a net change of -5 holders.
- The largest Lifecore Biomedical buyer in Q2 2022 was 22NW LP, an estimated $1.17M added.
- The largest Lifecore Biomedical seller in Q2 2022 was Fuller & Thaler Asset Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q2 2022.